Venlafaxine

Pharma industry sponsors dominate clinical cancer research, enrolling over eight times more patients than federally sponsored trials. This shift, which has dramatically increased over decades, benefits drug discovery but skews research priorities towards new drug approvals. Federally-funded trials address broader research questions and show higher demographic diversity. The influx of pharma-sponsored research raises concerns about potential bias in reported drug efficacy.

Diabetic Peripheral Neuropathy market to surge due to increasing prevalence and awareness, with multiple-stage pipeline products revolutionizing market dynamics. Key companies include Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex Pharmaceuticals, Helixmith, and Lexicon Pharmaceuticals. Emerging therapies such as QUTENZA (capsaicin) and TARLIGE (mirogabalin besylate) are expected to drive market growth.

Drug studies funded by manufacturers report 50% higher efficacy; Tamar Oostrom's research suggests sponsors selectively publish favorable trials, affecting drug use and patient outcomes.

Viatris announces positive Phase 3 results for EFFEXOR in treating GAD in Japanese adults, showing superiority over placebo in anxiolytic effects and a favorable safety profile.

Philly biotech Adaptimmune prepares to produce its first doses of a novel cancer treatment, Tecelra, for synovial sarcoma. Pennsylvania faces the nation's largest whooping cough outbreak, and local hospitals grapple with IV fluid shortages due to Hurricane Helene. Philadelphia sees a drop in overdose deaths but racial disparities in mortality are widening.

EFFEXOR® met primary and secondary efficacy endpoints in a Phase 3 study for GAD in Japanese adults, showing superior anxiolytic effects and a well-tolerated safety profile. The study achieved its primary objective of superiority over placebo at 8 weeks based on the Hamilton Anxiety Rating Scale (HAM-A) total score change. All seven secondary efficacy endpoints were also met, confirming superiority compared to placebo. EFFEXOR® was generally well-tolerated, with low discontinuation rates due to adverse events and no serious TEAEs observed. The PMDA submission is targeted for 2025.

Psychiatric drugs show 50% higher efficacy in trials funded by manufacturers, attributed to 'sponsorship effect' and publication bias, according to a study by Tamar Oostrom. The study, published in the Journal of Political Economy, analyzed double-blind RCTs and found that adding unpublished trials reduced the sponsorship effect by 20%, indicating most of the effect is due to publication bias. Preregistration has helped reduce this bias since 2005, but it doesn't address past approvals based on potentially biased evidence.